<DOC>
	<DOCNO>NCT01797653</DOCNO>
	<brief_summary>Randomized control trial ( therapeutic vs. placebo CPAP ) include 46 patient obstructive sleep apnea ( OSA ) define physiological effect continuous positive airway pressure ( CPAP ) therapy withdrawal myocardial perfusion dermal renal microvascular function 2 week period .</brief_summary>
	<brief_title>Randomized-controlled Trial ( RCT ) CPAP-withdrawal Microvascular Function OSA</brief_title>
	<detailed_description />
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>Inclusion criterion : Objectively confirm OSA ( time original diagnosis ) oxygen desaturation index ( ODI , =4 % dip ) &gt; 20/h ESS &gt; 10 . Currently &gt; 20/h oxygen desaturations ( =4 % dip ) ambulatory nocturnal pulse oximetry perform end 4night period without CPAP . Treated CPAP 12 month , minimum compliance 4h per night , AHI &lt; 10 treatment ( accord CPAP machine download data ) . Current ESS &lt; 10 . Exclusion criterion : Previous ventilatory failure ( awake SpO2 &lt; 93 % PaCO2 &gt; 6kPa ) . Unstable , untreated coronary peripheral artery disease , severe arterial hypertension hypotension ( &gt; 180/110 &lt; 90/60mmHg ) Previously diagnose CheyneStokes breathe . Current professional driver ; Any previous sleep related accident . Age &lt; 20 &gt; 75 year trial entry . Acute inflammatory disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>